Antibody-drug conjugates (ADCs) represent a ground-breaking fusion of precision medicine and cancer treatment. These innovative therapies combine the targeting specificity of monoclonal antibodies with the potent cytotoxicity of chemotherapeutic drugs. The antibody component precisely homes in on cancer cells, while the attached drug payload delivers a highly targeted punch, minimizing damage to surrounding healthy tissues. This nuanced approach enhances the therapeutic index and reduces systemic side effects commonly associated with traditional chemotherapy. ADCs have shown remarkable efficacy in treating various cancers, offering new hope for patients with challenging malignancies.
As the landscape of cancer treatment evolves, antibody-drug conjugates stand out as a promising avenue, epitomizing the intersection of advanced science and compassionate care in the fight against cancer. As research continues to advance, the development of next-generation ADCs holds promise for even greater precision and effectiveness in the fight against cancer. The era of antibody-drug conjugates represents a significant leap forward in personalized cancer therapy, ushering in a new paradigm of treatment that maximizes efficacy while minimizing the impact on healthy tissues.
Submit your abstract Today
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Exploring classical ayurvedic drugs in hypertension
Prashant Bhokardankar, Datta Meghe Ayurved College, India
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : A unique role and and impact of catalytic antibodies (abzymes) in clinical practice: A novel strategy for predicting and preventing relapse in chronic autoimmune conditions
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : The promise of nanotechnology in personalized & precision medicine: Drug discovery & development being partnered with nanotechnologies via the revolution at the nanoscale
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : The promising future of the unique translational tool to manage beta-cell population renewal and regeneration to secure the post-diabetic period
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Easily injectable, organic solvent free self assembled hydrogel platform for endoscope mediated gastrointestinal polypectomy
Hitasha Vithalani , IIT Gandhinagar, India
Title : Bridging tradition and innovation: Inorganic meets green synthesis
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy